<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270032</url>
  </required_header>
  <id_info>
    <org_study_id>AI-Breast-US</org_study_id>
    <nct_id>NCT04270032</nct_id>
  </id_info>
  <brief_title>Using Deep Learning Methods to Analyze Automated Breast Ultrasound Images, to Establish a Diagnosis, Therapy Assessment and Prognosis Prediction Model of Breast Cancer.</brief_title>
  <official_title>To Build and Evaluate a Precise Diagnosis, Therapy Assessment and Prognosis Prediction Model of Breast Cancer Based on Artificial Intelligence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of the Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xidian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of the Fourth Military Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is using a deep learning method to analyze the automated breast
      ultrasound (ABUS) imagings, establish and evaluate a diagnosis, therapy assessment and
      prognosis prediction model of breast cancer. The model would provide important references for
      further early prevention, early diagnosis and personalized treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Establishing a database By collecting ABUS and comprehensive breast image data,
           essential information, clinical treatment information, prognosis, and curative effect
           information, a complete breast image database is constructed.

        2. Marking ABUS image Three doctors use a semi-automatic method to frame the lesions on the
           image.

        3. Building the model Using the deep learning method to preprocess, analyze and train the
           marked image, and finally get a model diagnosis, efficacy evaluation and prognosis
           prediction model of breast cancer.

        4. Evaluating the model 1）Self-validation： Analyze the sensitivity, AUC of the breast
           cancer diagnosis model and the false-positive number on each ABUS volume.

      2) Compared the sensitivity, AUC and the false-positive number with a commercial diagnosis
      model.

      3)By analyzing the size and characteristics of the lesions after neoadjuvant chemotherapy,
      and predicting the OS and DFS time, the therapy assessment and prognosis prediction model
      were evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity</measure>
    <time_frame>4 years</time_frame>
    <description>Proportion of corrected-marked malignant lesions by the model</description>
  </primary_outcome>
  <primary_outcome>
    <measure>false-positive per volume</measure>
    <time_frame>4 years</time_frame>
    <description>the number of uncorrected-marked malignant lesions by the model</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under curve</measure>
    <time_frame>4 years</time_frame>
    <description>area under receiver operating characteristic (ROC) curve in percentage (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival(OS) time</measure>
    <time_frame>up to 10 years</time_frame>
    <description>It measures the time from the date of cancer diagnosis to any cause of death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival (DFS) time</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The time that the patient is free of the signs and symptoms of a disease after treatment.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>malignant group</arm_group_label>
    <description>women with malignant lesions confirmed by pathology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benign group</arm_group_label>
    <description>women with benign lesions confirmed by pathology or stable in follow-up &gt; 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal group</arm_group_label>
    <description>women have normal images with follow up &gt; 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ABUS</intervention_name>
    <description>Using deep learning method to analyze and extract the features of automated breast ultrasound images</description>
    <arm_group_label>benign group</arm_group_label>
    <arm_group_label>malignant group</arm_group_label>
    <arm_group_label>normal group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients over 18 years old from two countries (China and Korea).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients over 18 years old who come to the two centers for physical examination
             or treatment;

          2. Complete basic information and image data

        Exclusion Criteria:

          1. There is no complete ABUS image data;

          2. The image quality of ABUS image is poor;

          3. In multifocal breast cancer, the correlation between the tumor in the image and the
             postoperative pathological examination is uncertain.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongping Song, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing hospital of The fourth military medical university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongping Song, MD</last_name>
    <phone>86 029 84771663</phone>
    <email>song.hp@foxmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hongping song, Ph.D</last_name>
      <phone>+86-29-84771663</phone>
      <email>Songhp@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>hongping song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of the Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Song Hongping</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

